Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biosensor Firm Grapheal Raises €1.9M, Plans to Develop SARS-CoV-2 Test

Biosensor Firm Grapheal Raises €1.9M, Plans to Develop SARS-CoV-2 Test

Feb 09, 2021
|
staff reporter

NEW YORK — French biosensor developer Grapheal said on Tuesday that it has raised €1.9 million ($2.3 million) that it will use in part to support the development of a saliva-based SARS-CoV-2 antigen test.

The funding includes seed money from Novalis Biotech's Acceleration Fund, grants, and convertible notes and loans from French investment bank Bpifrance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Apr
06
Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

What's Popular?

In Infectious Disease

  1. OraSure Technologies Updates Plan for SARS-CoV-2 Antigen Self-Test

    Premium

  2. Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

  3. Lumos Diagnostics Signs Canadian Distribution Deal for Acute Respiratory Infection Assay

  4. Reference Labs Take Diverse Approaches to Mitigating COVID-19 Sample Shipping Delays

    Premium

  5. LightDeck Sketches Commercial Plans for Five-Minute Multiplex Tests For SARS-CoV-2, Other Conditions

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.